Get started
Author

Julie M. Furze

Observed names: J Furze, J M Furze, J. Furze, J. M. Furze, J.M. Furze, Julie Furze, Julie M Furze
Observed institutions: Scripps Research Institute, The Pirbright Institute, Centre for Human Genetics, University of Cambridge, University of Oxford, Jenner Institute
OpenAlex ID: A5033789796
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
2020 · Merryn Voysey, Sue Ann Costa Clemens, et al. · The Lancet · 4,692
PDF
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
2020 · Pedro M Folegatti, Katie J Ewer, et al. · The Lancet · 2,414
PDF
Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine
2021 · Merryn Voysey, Sue Ann Costa Clemens, et al. · The Lancet · 1,128
PDF
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
2020 · Katie J. Ewer, Jordan R. Barrett, et al. · Nature Medicine · 585
PDF
Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans.
1995 · A Vitiello, G Ishioka, et al. · Journal of Clinical Investigation · 334
Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex.
1991 · A Vitiello, D Marchesini, et al. · The Journal of Experimental Medicine · 310
PDF
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
2020 · Jordan R. Barrett, Sandra Belij-Rammerstorfer, et al. · Nature Medicine · 309
PDF
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
2021 · Amy Flaxman, Natalie G Marchevsky, et al. · The Lancet · 247
PDF
Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine Vectors at Supraphysiological Temperatures in Carbohydrate Glass
2010 · Robert Alcock, Matthew G. Cottingham, et al. · Science Translational Medicine · 162
Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection in Vivo
1991 · Philip R. Tempest, Patricia Bremner, et al. · Nature Biotechnology · 160
Role of Alpha/Beta Interferons in the Attenuation and Immunogenicity of Recombinant Bovine Respiratory Syncytial Viruses Lacking NS Proteins
2003 · Jean-Francois Valarcher, Julie Furze, et al. · Journal of Virology · 149
Neutralization of Plasmodium falciparum Merozoites by Antibodies against PfRH5
2013 · Alexander D Douglas, Andrew R Williams, et al. · The Journal of Immunology · 144
PDF
Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus
1992 · J. Arbiza, G. Taylor, et al. · Journal of General Virology · 142
Role of T-lymphocyte subsets in recovery from respiratory syncytial virus infection in calves
1995 · G Taylor, L H Thomas, et al. · Journal of Virology · 138
Enhancing Blockade of Plasmodium falciparum Erythrocyte Invasion: Assessing Combinations of Antibodies against PfRH5 and Other Merozoite Antigens
2012 · Andrew R. Williams, Alexander D. Douglas, et al. · PLoS Pathogens · 132
PDF
Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge
1986 · E J Stott, L A Ball, et al. · Journal of Virology · 121
Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies
1992 · G. Taylor, E. J. Stott, et al. · Journal of General Virology · 117
Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA)
2008 · Matthew G. Cottingham, Rikke F. Andersen, et al. · PLoS ONE · 93
PDF
Antigenic heterogeneity of the attachment protein of bovine respiratory syncytial virus
1994 · J. Furze, G. Wertz, et al. · Journal of General Virology · 88
Recombinant vaccinia viruses expressing the F, G or N, but not the M2, protein of bovine respiratory syncytial virus (BRSV) induce resistance to BRSV challenge in the calf and protect against the development of pneumonic lesions.
1997 · G Taylor, L H Thomas, et al. · Journal of General Virology · 73
Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice
2013 · George M Warimwe, Gema Lorenzo, et al. · Virology Journal · 61
PDF
Antigenic structure of the central conserved region of protein G of bovine respiratory syncytial virus
1997 · J P Langedijk, R H Meloen, et al. · Journal of Virology · 56
PDF
Antigenically Distinct G Glycoproteins of BRSV Strains Share a High Degree of Genetic Homogeneity
1997 · J.M. Furze, S.R. Roberts, et al. · Virology · 55
Characterization of the epitope for anti-human respiratory syncytial virus F protein monoclonal antibody 101F using synthetic peptides and genetic approaches
2007 · Sheng-Jiun Wu, Albert Schmidt, et al. · Journal of General Virology · 53
Recognition of bovine respiratory syncytial virus proteins by bovine CD8+ T lymphocytes
2003 · Ruth M. Gaddum, Roy S. Cook, et al. · Immunology · 49
PDF
Works count: 40
Citation count: 12,080
H-index: 29
I10-index: 34
Year
Topic
Type